Materials and Methods
Mice. AB6F, (A/J x C57BL/6) female mice were used when they were 10-12 wk old. They were purchased from The Trudeau Institute Animal Breeding Facility, and were free of common viral pathogens according to the results of tests routinely performed by Charles River Professional Services, Wilmington, MA .
Tumor. The SAl spindle cell sarcoma syngeneic in A/J mice was obtained some years ago from The Jackson Laboratories, Bar Harbor, ME . It was passaged as an ascites and prepared for initiating tumors as described previously (13) . Tumors were initiated intradermally in the abdominal region by implanting 106 tumor cells in 0 .05 ml of PBS. Tumor growth and regression was followed by monitoring changes in the mean of two diameters measured at right angles with dial calipers .
Endotoxin and TNF. Murine rTNF was a gift from Dr. Jan Tavernier of the University of Ghent, Belgium . It has a specific activity of 1 .37 x 108 U/mg protein, and contained <10 ng endotoxin/mg (13) . Endotoxin (Salmonella enteritidis, batch 3105-25) was obtained from Difco Laboratories, Detroit, MI . Both reagents were dissolved at appropriate concentrations in PBS . They were injected in a volume of 0 .2 ml in a lateral tail vein on day 9 of tumor growth . The dose of rTNF was 10 5 U, and the dose of endotoxin 25 /Ag .
Quantifying the Tumor Hemorrhagic Reaction . The rate and extent of TNF-or endotoxin-induced intratumor hemorrhaging were quantified by measuring the accumulation in the tumor of "Cr-labeled syngeneic RBCs infused 1 h earlier in a lateral tail vein (13) . Briefly, AB6F1 mice were bled by cardiac puncture into a syringe containing citric acid/dextrose solution . The RBCs were pelleted and washed by centrifugation in RPMI 1640 medium . To each 0 .5 ml of packed red cells was added 0 .5 ml of RPMI 1640 medium containing 100 ACi of Nat"CrO4 having a specific activity of 250-500 mCi/mg (Amersham Corp ., Arlington Heights, IL) . The RBCs were suspended and incubated for 1 h at 37°C, washed three times, and resuspended in 2 ml of PBS for intravenous infusion . Each mouse was given an infusion of 0 .2 ml of the "Cr-labeled RBC suspension in a lateral tail vein 1 h before treatment with endotoxin or rTNE To measure intratumor hemorrhaging five mice were killed at 1, 2, 4, and 6 h after injection of endotoxin or rTNF, their tumors were excised, placed in glass vials, and the "Cr content per tumor determined with a Rack Gamma II Counter (LKB Instruments, Inc ., Gaithersburg, MD) . The results are presented as means of the total counts per minute per tumor.
Assay for TNF. An assay based on the procedure of Wang et al . (14) was used . Briefly, 1 .5 x 10 4 murine L929B cells in 100 p,l of Eagle's MEM (Microbiological Associates, Walkersville, MD) containing 5 % FCS and antibiotics were placed in wells of 96-well microtiter plates and incubated overnight at 37°C in a 5% C02 humidified incubator. Sequential twofold dilutions of the TNF containing extracts were made in the same medium containing 2 lcg of actinomycin D (Calbiochem-Behring Corp ., La Jolla, CA), and 100 pl of each dilution added to replicate wells containing the L929B target cells . After 24 h of incubation cytotoxicity was scored microscopically. The cytotoxicity titer (U/ml) is defined as the highest dilution of the test material capable of causing 50% or more destruction of the monolayer of L929B cells . The assay was used to determine cytotoxic titers of extracts of tumors from control and endotoxin-treated mice . Extracts were made by homogenizing whole tumors (10% wt/vol) in PBS (pH 7 .4) containing 10% FCS. Homogenization was done on ice with a motorized blender. The homogenates were centrifuged to pellet tissue debris, and the clarified supernatants assayed as above . Previous studies have shown (4) that TNF is stable during the extraction procedure, and that all endotoxin-induced cytotoxic activity in tumor extracts is neutralizable with an anti-rTNF antibody.
Glucocorticoids. Cortisone acetate suspended in saline (Merck, Sharp and Dohme, West Point, PA) and dexamethasone 21-acetate (Sigma Chemical Co., St . Louis, MO) dissolved in ethanol and then in PBS were injected in a volume of 0 .2 ml subcutaneously in the nape of the neck in a dose of 2 or 1 mg, respectively.
Results
Glucocorticoid Treatment Inhibits Endotoxin-induced Hemorrhagic Necrosis and Regression.
The first experiments were designed to investigate whether intradermal injection of 2 mg of cortisone acetate would prevent a 25-jug dose of endotoxin given intravenously 12 h later from causing hemorrhagic necrosis and regression of a 9-d SA1 sarcoma. As can be seen in Fig. 1 , whereas endotoxin treatment caused an extensive hemorrhagic reaction in and subsequent regression of the SAl sarcoma growing in control mice, it caused neither hemorrhagic necrosis nor complete regression of the same sized tumor in glucocorticoid-treated mice . There was a small degree of endotoxin-induced regression of the tumor in cortisone-treated mice, but progressive tumor growth soon resumed. Fig. 2 shows the results of an experiment designed to determine whether dexamethasone was also capable of inhibiting endotoxin-induced hemorrhagic necrosis . It can be seen that this glucocorticoid given 12 h before endotoxin was as effective as cortisone acetate in inhibiting hemorrhagic necrosis . Dexamethasone was also as capable of inhibiting tumor regression (results not shown) .
Glucocorticoid Treatment Inhibits Intratumor TNF Production . Table I shows the results of an experiment that measured the ability of cortisone acetate or dexamethasone to inhibit endotoxin-induced synthesis of TNF in a 9-d SA1 sarcoma and in the host at large. This experiment involved measuring the capacity of serial dilutions DAYS HOURS NORTH AND HAVELL 705
The ability of a 25 -,ug i.v. dose of endotoxin (ENDO) given on day 9 of tumor growth (arrow) to cause intratumor hemorrhaging (right panel) andtumor regression (left paneo was severely inhibited by an intradermal injection of cortisone acetate 12 h before endotoxin (CORT + ENDO). Cortisone acetate alone had little effect on tumor growth . Means of five mice per group. FIGURE 2. Dexamethasone (ENDO + DEXAM) was as effective as cortisone acetate (ENDO + CORT) at inhibiting intratumor hemorrhaging caused by endotoxin (ENDO) given on day 9 of tumor growth . The tumor hemorrhagic reaction was measured at its peak 6 h after giving endotoxin. Means of five tumors per group. of extracts of tumors and organs from glucocorticoid-treated and control mice to lyse L929B target cells in vitro. A previous study showed (4) that all of the cytotoxicity extractable from the tumors and organs of endotoxin-treated mice is due to the presence of TNF, and that peak quantities of TNF are synthesized 2 h after endotoxin is given. It can be seen that 2 h after endotoxin treatment appreciable quantities of TNF were present in the tumors, spleens, and blood of endotoxin-treated control mice, and that by far the largest quantity of TNF was present in the tumors . In contrast, greatly reduced quantities (10% or less of controls) of TNF were present in the tumors, spleen, and blood of endotoxin-treated mice pretreated with glucocorticoids.
Glucocorticoid Treatment Has No Effect on the Ability of Exogenous TNF to Cause Tumor Hemorrhagic Necrosis and Regression . It is well documented that intravenously injected natural or rTNF results in extensive hemorrhagic necrosis of the centers of murine tumors, and that in the case of the SA1 sarcoma, hemorrhagic necrosis is followed by complete tumor regression (4). Given the published evidence that TNF is the mediator of endotoxin-induced regression (4), and the evidence above that glucocorticoids inhibit endotoxin-induced hemorrhagic necrosis by inhibiting endogenous TNF synthesis, it was anticipated that glucocorticoid treatment would have no effect on the ability of exogenous TNF to cause hemorrhagic necrosis of the SA1 sarcoma.
It can be seen in Fig. 3 that 2 mg of cortisone acetate given intradermally to mice bearing a day 9 SAl sarcoma had no effect on the ability of 10 5 U of rTNF given intravenously 12 h later to cause hemorrhagic necrosis and subsequent complete tumor regression .
Glucocorticoid Treatment Given after the Hemorrhagic Reaction Does Not Prevent Endotoxin from Causing Tumor Regression. It was shown above that the ability of rTNF to cause hemorrhagic necrosis and subsequent regression of the SAl sarcoma was not affected by pretreating the host with glucocorticoids. However, it is known (4, 13) that complete regression of this tumor requires that the host possesses an adequate level of concomitant antitumor immunity. This means that glucocorticoid treatment does not inhibit host antitumor immunity. It was anticipated, therefore, that glucocorti- Evidence that the ability of 10 5 U of rTNF (TNF) given intravenously on day 9 of tumor growth to cause intratumor hemorrhaging ( Cortisone acetate given intradermally before (ENDO + CORT, -12 h), but not after (CORT + ENDO, + 5 h) endotoxin on day 9 of tumor growth, inhibited endotoxin-induced tumor regression (ENDO). Means of five mice per group. coid treatment would not prevent endotoxin-induced tumor regression if given after endotoxin has already caused a hemorrhagic reaction in the tumor.
It was found (Fig . 4) that, whereas cortisone acetate given 12 h before endotoxin inhibited tumor regression, cortisone acetate given 5 h after endotoxin, when the tumor hemorrhagic reaction was almost complete, was without effect . It is apparent, therefore, that cortisone acetate inhibits endotoxin-induced regression solely by inhibiting hemorrhagic necrosis .
Discussion
This study shows that the ability of endotoxin to cause hemorrhagic necrosis and subsequent regression of an established subcutaneous SA1 sarcoma is inhibited by treating the tumor-bearing mice with glucocorticoids 12 h before giving them endotoxin. Inhibition of endotoxin-induced hemorrhagic necrosis was shown to be associated with inhibition of endotoxin-induced TNF production in the tumor and in the host at large. On the other hand, glucocorticoid treatment had no effect on the ability of exogenous TNF to cause hemorrhagic necrosis and regression of the SAl sarcoma. Given the published evidence showing that TNF is the primary mediator of endotoxin-induced tumor hemorrhagic necrosis (4), the results presented here strongly suggest that glucocorticoids inhibit the antitumor action of endotoxin by inhibiting its ability to induce the production of TNF This is not to say that TNF alone is responsible for endotoxin-induced tumor hemorrhagic necrosis . It may also require the participation of already formed host molecules, such as complement component C5 (15) , or of induced molecules, such as IL-1 and other cytokines. However, if other induced molecules are involved, their induction would need to be resistant to the doses of glucocorticoids used here . It is known, in this connection, that glucocorticoids can inhibit the synthesis of IL-1 (16) (17) (18) , as well as TNF (12), by host cells in vitro, both at the level of gene transcription and translation . It seems likely, therefore, that IL-1 is not needed for TNF mediated tumor hemorrhagic necrosis . Even so, a role for IL-1 and other induced cytokines cannot be excluded until it is formally demonstrated that they are not involved .
As for TNF itself, it is likely that intratumor macrophages are mainly responsible for its production in the tumor. It is known that macrophages are major producers of TNF (8) , that these cells can be well represented in tumors (9) , and that TNF appears to be responsible, at least in part, for the ability of macrophages to kill certain tumor cells in vitro (10, 11) . It seems almost certain, however, that TNF does not cause tumor hemorrhagic necrosis by directly destroying tumor cells in vivo. On the contrary, it was elegantly demonstrated many years ago (18) that endotoxininduced tumor hemorrhagic necrosis is caused by a breakdown in the tumor's vasculature and consequently in ischemic death of most of the central part of the tumor. This could result from a direct cytotoxic action of TNF on vascular endothelial cells, as has shown to be the case in other models of TNFinduced hemorrhagic necrosis (19) . In the study presented here intratumor hemorrhaging was measured in terms of the intratumor extravasation of S 1 Cr-labeled syngeneic red blood cells infused intravenously shortly before endotoxin or TNF was given .
It needs to be pointed out that the endotoxin-induced vascular breakdown and ischemic death of the center of the tumor is not sufficient to cause complete tumor regression . In order for the rim of living tumor tissue that survives hemorrhagic necrosis to undergo complete regression, it is necessary for the host to be in the process of generating an adequate level of concomitant antitumor immunity (4). The finding that glucocorticoids failed to inhibit the ability of exogenous TNF to cause hemorrhagic necrosis, or subsequent tumor regression, means that these compounds did not significantly depress antitumor immunity. Therefore, their ability to inhibit the antitumor action of endotoxin must have been based solely on their ability to inhibit hemorrhagic necrosis . It is apparent, therefore, that hemorrhagic necrosis serves to reduce the tumor burden to a size that can be completely rejected by an otherwise subtherapeutic level of concomitant immunity.
Because the tumor hemorrhagic reaction can be viewed as a tissue destructive inflammatory reaction caused by the local synthesis of TNF, its inhibition by glucocorticoids indicates that it might serve as a useful model to study in more detail the antiinflammatory action of glucocorticoids and antiinflammatory agents in general.
Intravenous injection of 25 ug of bacterial endotoxin on day 9 of growth of the SAl sarcoma results in extensive necrosis of the core of this tumor and in its subsequent complete regression . Tumor hemorrhagic necrosis and regression failed to ' given a subcutaneous injection of cortisone acetate or dexamethasone 12 h before being giving endotoxin. Inhibition of tumor hemorrhagic necrosis and regression by glucocorticoids was associated with inhibition of endotoxin induced intratumor TNF production that normally takes place several h after endotoxin is given . In contrast, glucocorticoids had no effect on the ability of intravenously injected rTNF to cause tumor hemorrhagic necrosis and regression. The results lend further support to the belief that TNF is the predominant mediator of endotoxininduced hemorrhagic necrosis of established murine tumors, and that hemorrhagic necrosis is a prerequisite for the immunologically mediated regression that follows .
